Evaluation of PegIntron in control of hepatitis C Cirrhosis 3

Trial Profile

Evaluation of PegIntron in control of hepatitis C Cirrhosis 3

Completed
Phase of Trial: Phase III

Latest Information Update: 02 Nov 2010

At a glance

  • Drugs Peginterferon alfa-2b; Ribavirin
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Acronyms EPIC-3
  • Sponsors Schering-Plough
  • Most Recent Events

    • 18 Apr 2010 Results from EPIC3 were presented at the 45th Annual Meeting of the European Association for the Study of the Liver.
    • 30 Oct 2009 Results from EPIC-3 Maintenance Trial presented at the 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD).
    • 26 Apr 2009 Results from EPIC-3 Maintenance Trial presented at EASL 2009.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top